What stage of chronic kidney disease corresponds to a glomerular filtration rate of 49 mL/min/1.73 m²?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

A GFR of 49 mL/min/1.73 m² is Stage 3a Chronic Kidney Disease

A glomerular filtration rate of 49 mL/min/1.73 m² corresponds to Stage 3a chronic kidney disease (CKD), defined as mildly to moderately decreased kidney function with GFR between 45-59 mL/min/1.73 m² 1, 2.

Understanding the CKD Staging System

The National Kidney Foundation's K/DOQI classification system, which has been internationally adopted and refined by KDIGO, stages chronic kidney disease based on GFR levels 1:

  • Stage 1: GFR ≥90 mL/min/1.73 m² (with kidney damage markers)
  • Stage 2: GFR 60-89 mL/min/1.73 m² (with kidney damage markers)
  • Stage 3a: GFR 45-59 mL/min/1.73 m²
  • Stage 3b: GFR 30-44 mL/min/1.73 m²
  • Stage 4: GFR 15-29 mL/min/1.73 m²
  • Stage 5: GFR <15 mL/min/1.73 m² (kidney failure)

The subdivision of Stage 3 into 3a and 3b was introduced because these ranges carry different risk profiles for adverse outcomes and disease progression 2.

Clinical Significance of Stage 3a CKD

At a GFR of 49 mL/min/1.73 m², this patient has lost more than half of normal adult kidney function (normal GFR in young adults is approximately 120-130 mL/min/1.73 m²) 1. This level of kidney function marks an important threshold where:

  • The prevalence of CKD complications begins to increase 1
  • Drug dosage adjustments become necessary 1
  • Cardiovascular risk is elevated 1
  • Evaluation and treatment of complications such as anemia, malnutrition, and bone disease should be initiated 1

Important Clinical Considerations

Complete Classification Requires Albuminuria Assessment

The modern CKD classification system uses a "CGA" approach—Cause, GFR category, and Albuminuria category 2, 3. A GFR of 49 alone tells you the "G" category (G3a), but complete risk stratification requires knowing the albuminuria level:

  • Normal/mildly increased albuminuria (<30 mg/g): Moderate risk
  • Moderately increased albuminuria (30-300 mg/g): High risk
  • Severely increased albuminuria (>300 mg/g): Very high risk

3

Age-Related Decline vs. True CKD

While GFR naturally declines with age (approximately 17% of persons over 60 have eGFR <60 mL/min/1.73 m²), decreased GFR in elderly patients remains an independent predictor of adverse outcomes including death and cardiovascular disease 1. The definition of CKD is the same regardless of age 1.

Confirmatory Testing May Be Warranted

For patients with eGFR 45-59 mL/min/1.73 m² without other markers of kidney damage, KDIGO suggests measuring cystatin C to confirm the CKD diagnosis 2. However, this recommendation has limitations in certain populations like kidney transplant recipients 4.

Clinical Action Plan for Stage 3a CKD

At this stage, the following interventions should be implemented 1:

  • Aggressive blood pressure control
  • Treatment of comorbid conditions
  • Interventions to slow disease progression
  • Cardiovascular risk reduction measures
  • Evaluation and treatment of complications (anemia, bone disease, malnutrition)
  • Medication dose adjustments as needed

Referral to a nephrologist is not yet mandatory at Stage 3a but should be considered if there is uncertainty about etiology, difficult management issues, or rapidly progressing disease 1. Mandatory nephrology referral is recommended when GFR falls below 30 mL/min/1.73 m² (Stage 3b or worse) 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.